Skip to content
OpenCapital
Get started

Revvity RVTY Life Sciences — Segment operating income

Similar metrics at other companies

STERIS logo
STELife Sciences: — Segment operating income
$61.8M+6.4%
STERIS logo
STELife Science Member — Segment operating income
$58.13M+2.5%
STERIS logo
STELife Sciences: — Operating Income (Loss), Before Adjustments
$61.8M+6.4%
Agilent Technologies logo
ALife Sciences and Diagnostics Markets — Income from operations
$161M+24.8%
STERIS logo
STELife Science Member — Operating Income (Loss), Before Adjustments
$58.7M+11.6%
PEA
PEAKLifescience — Profit Loss
——

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%—
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept revv:SegmentOperatingIncome.

The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revvity's life sciences — segment operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revvity's life sciences — segment operating income?
Revvity (RVTY) reported life sciences — segment operating income of $103.98M in Q1 2026.
How has Revvity's life sciences — segment operating income changed year-over-year?
Revvity's life sciences — segment operating income decreased by 1.6% year-over-year, from $105.71M to $103.98M.
What is the long-term trend for Revvity's life sciences — segment operating income?
Over 3 years (2022 to 2025), Revvity's life sciences — segment operating income has grown at a -3.1% compound annual growth rate (CAGR), from $503.24M to $458.26M.
What does life sciences — segment operating income mean?
The core operating profit of the Life Sciences segment.
How do you interpret life sciences — segment operating income?
Higher operating income indicates strong operational efficiency and pricing power within the segment.
How does life sciences — segment operating income compare across companies?
Standard 'Segment Operating Profit' or 'EBIT' used to compare business unit performance.